Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone for outpatient treatment of COVID-19
IRCT20171219037964N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of prednisolone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Treatment failure. Started Dec 2020; status: completed.
02
Drugs
prednisolone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20171219037964N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171219037964N2.